Early ALS drug trial halted after safety check
NCT ID NCT03757351
Summary
This was an early-stage study to check the safety and side effects of an experimental oral drug called DNL747 in people with ALS. Fifteen participants took the drug or a placebo in a crossover design. The main goal was to see how well the drug was tolerated and how it behaved in the body, not to test if it improved ALS symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bioclinica
Orlando, Florida, 32806, United States
-
CHDR
Leiden, South Holland, 2333, Netherlands
-
PRA Health Sciences
Salt Lake City, Utah, 84124, United States
Conditions
Explore the condition pages connected to this study.